Main Profile

Sterile liquid and Lyophilized powder Biotechnological product production, filling and packaging

Description in a few words:

CinnaGen Pharmaceuticals has been operating in the pharmaceutical sector since 1994 and is the largest biotechnological pharmaceutical company in MENA with 2,300 employees. The investment value of the factory in Turkey is €30 million in physical assets and €70 million into R&D and technology transfer, which represents 20-30% of annual turnover. The company’s portfolio covers highly prioritized therapeutic areas, including: cancer, CNS, Central Nervous System Diseases, Rheumatoid Arthritis, Hematological Diseases, Rare Diseases and severe Autoimmune Diseases. Cinnagen İlaç currently has 12 products under development including the most promising biotechnological drugs globally.

Current Leadership:

Ferhat Farşi, CEO

Founding Year: 1994

In the last 25 years, CinnaGen has become a creator of its own master cell lines, which means we are not dependent on other companies. The most important step in biotechnology is creating the proteins or polypeptides in-house, because it enables a high level of control over the cost of the products, increasing your competitiveness on a global scale.


Number of machinery in Production and capacities: solid, liquid, sterile:

Manufacturing Plant in Çerkezköy, Turkey

Main product categories or therapies of focus

The product portfolio includes Recombinant Protein and Monoclonal Antibody Medicines, which are used for the treatment of cancer, Central Nervous System Diseases, Rheumatoid Arthritis, Hematological Diseases, Rare Diseases and severe Autoimmune Diseases.

Number of APIs produced


Total number of delivered boxes/year



R&D focus

Founded in 1994, CinnaGen is the largest manufacturer of biotechnological drugs in the MENA Region, following the continuous development approach. CinnaGen İlaç allocates 30-40% of its revenues on R&D and aims to be among the top 10 biotechnology companies worldwide, with plans to add 12 new products under development to its portfolio covering major gaps in biotechnological drugs globally.


Export % in revenues:

Targeted US$100 million export volume to 20 countries by 2023

List of export countries:

Sri Lanka, Moldova, Algeria, Bosnia and Herzegovina, Jordan, Serbia, Vietnam, Senegal, Ecuador, Qatar, India, Morocco

In More Depth

Number of employees

2,300 international, 54 in Turkey

GMP certificates

GMP/GLP for manufacturing of Biotechnological drugs

USP/ or a differentiating fact

CinnaGen İlaç is the first Monoclonal Antibody Manufacturer in Turkey